Annals of Oncology 10:S3-S8, 1999
© 1999 European Society for Medical Oncology
Symposium Articles |
Neuroendocrine gastrointestinal tumors - A condensed overview of diagnosis and treatment
Department of Internal Medicine, University Hospital Uppsala, Sweden
Correspondence to: Prof. K. Öberg, Department of Internal Medicine, University Hospital, S-75185 Uppsala, Sweden
Neuroendocrine gut and pancreatic tumors are rather rare malignant diseases which has gained increased attraction through the last decennium, possibly through development of new diagnostic and therapeutic methods. Histopathology demonstrating the common neuroendocrine features of these tumors has been the diagnostic corner stone for long, but today it should be suppled with information about the tumor biology. An excellent biochemical marker which is easy to analyze in serum or plasma is chromogranin A, which is a gycoprotein that is stored and released from neuroendocrine cells. This marker can be used for diagnosis and follow-up of the patients.
Somatostatin receptor scintigraphy has been one of the most important diagnostic tools for staging of the disease and also indicating sensitivity to treatment with somatostatin analogues. It is a general agreement that almost every patient should be subjected to this procedure before or during the treatment course.
From the therapeutic point of view, surgery is nowadays more extensive aiming at reducing the tumor mass in patients who could not be cured by surgery alone. Other means of tumor reduction is liver dearterialization by embolization with starch spheres.
The medical treatment of neuroendocrine tumors has made a real break through with the introduction of somatostatin analogues, particularly octreotide, and today most of the hormonally related symptoms can be controlled by this kind of treatment. Somatostatin analogues have also shown to be inhibitors of tumor growth and the latest development is tumor targeted radioactive treatment with Ytrium or Indium labelled octreotide. Long-acting formulation of somatostatin analogues have come into clinical use and significantly improved quality of life for patients with neuroendocrine tumors.
Other means of medical treatment are alpha interferons, which have shown particular effect in patients with midgut carcinoid tumors giving both biochemical and tumor responses.
Chemotherapy such as streptozotocin plus 5-fluorouracil (5-FU) or doxorubicin is still considered as first-line treatment in malignant endocrine pancreatic tumors but is combined with concomitant somatostatin analogue treatment.
In the future a multimodal treatment will further develop combining different agents and also somatostatin receptor subtype specific analogues will come into clinical use.
-interferon, chemotherapy, chromogranin A, octreotide, receptor scintigraphy, somatostatin, surgery
CiteULike 
Connotea 
Del.icio.us What's this?
This article has been cited by other articles:
|
|
 |
|
  S. N. Pinchot, K. Holen, R. S. Sippel, and H. Chen Carcinoid Tumors Oncologist, December 1, 2008; 13(12): 1255 - 1269. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 N Fazio, F de Braud, G Delle Fave, and K Oberg Interferon-{alpha} and somatostatin analog in patients with gastroenteropancreatic neuroendocrine carcinoma: single agent or combination? Ann. Onc., January 1, 2007; 18(1): 13 - 19. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 T. Delaunoit, J. Rubin, F. Neczyporenko, C. Erlichman, and T. J. Hobday Somatostatin Analogues in the Treatment of Gastroenteropancreatic Neuroendocrine Tumors Mayo Clin. Proc., April 1, 2005; 80(4): 502 - 506. [Abstract] [PDF]
|
|
|
|
 |
|
 G. Buccheri and D. Ferrigno Lung cancer: clinical presentation and specialist referral time Eur. Respir. J., December 1, 2004; 24(6): 898 - 904. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 L. T. Nordquist, G. R. Simon, A. Cantor, W. M. Alberts, and G. Bepler Improved Survival in Never-Smokers vs Current Smokers With Primary Adenocarcinoma of the Lung Chest, August 1, 2004; 126(2): 347 - 351. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Samyn, C. Fontaine, F. Van Tussenbroek, M. Pipeleers-Marichal, and J. De Greve Paraneoplastic Syndromes in Cancer: CASE 1. Polycythemia As a Result of Ectopic Erythropoietin Production in Metastatic Pancreatic Carcinoid Tumor J. Clin. Oncol., June 1, 2004; 22(11): 2240 - 2242. [Full Text] [PDF]
|
|
|
|
 |
|
 M. L. Schipper, A. Weber, M. Behe, R. Goke, W. Joba, H. Schmidt, T. Bert, B. Simon, R. Arnold, A. E. Heufelder, et al. Radioiodide Treatment after Sodium Iodide Symporter Gene Transfer Is a Highly Effective Therapy in Neuroendocrine Tumor Cells Cancer Res., March 15, 2003; 63(6): 1333 - 1338. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
D. Moro-Sibilot, M. Jeanmart, S. Lantuejoul, F. Arbib, M. H. Laverriere, E. Brambilla, and C. Brambilla Cigarette Smoking, Preinvasive Bronchial Lesions, and Autofluorescence Bronchoscopy Chest, December 1, 2002; 122(6): 1902 - 1908. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Miura, E. D. Bowman, R. Simon, A. C. Peng, A. I. Robles, R. T. Jones, T. Katagiri, P. He, H. Mizukami, L. Charboneau, et al. Laser Capture Microdissection and Microarray Expression Analysis of Lung Adenocarcinoma Reveals Tobacco Smoking- and Prognosis-related Molecular Profiles Cancer Res., June 1, 2002; 62(11): 3244 - 3250. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K Ueda, I Kawachi, M Nakamura, H Nogami, N Shirokawa, S Masui, A Okayama, and A Oshima Cigarette nicotine yields and nicotine intake among Japanese male workers Tob. Control, March 1, 2002; 11(1): 55 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H Kulaksiz, R Eissele, D Rossler, S Schulz, V Hollt, Y Cetin, and R Arnold Identification of somatostatin receptor subtypes 1, 2A, 3, and 5 in neuroendocrine tumours with subtype specific antibodies Gut, January 1, 2002; 50(1): 52 - 60. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
E. Brambilla, W.D. Travis, T.V. Colby, B. Corrin, and Y. Shimosato The new World Health Organization classification of lung tumours Eur. Respir. J., December 1, 2001; 18(6): 1059 - 1068. [Abstract] [Full Text] [PDF]
|
|